135P Camrelizumab plus chemotherapy as first-line therapy for NSCLC: A pooled analysis of two randomized phase III trials with extended follow-up. (December 2022)

• Record Type: Journal Article
• Authors: Zhou, C.; Chen, G.; Huang, Y.; Chen, J.; Cheng, Y.; Wang, Q.; Pan, Y.; Zhou, J.; Shi, J.; Xu, X.; Lin, L.; Zhang, W.; Zhang, Y.; Liu, Y.; Fang, Y.; Feng, J.; Wang, Z.; Tai, Y.; Ma, X.; Lu, X.
• Is Part Of: Immuno-oncology technology. Volume 16(2022)Supplement 1
• Publication Date: 2022-12
• Subjects: Cancer -- Immunotherapy -- Periodicals; 616.994061
• DOI: 10.1016/j.iotech.2022.100247
• Languages: English
• ISSNs: 2590-0188